PRL and neoplasm: Recently, some case reports have shown tumour shrinkage and prolactin level normalisation in resistant prolactinomas treated with pasireotide long-acting release, a second-generation somatostatin receptor ligand which binds to multiple SST receptors, but with a particularly high affinity for SST5 receptor [62,63].